Trial
NCT03433703
Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Eisai Inc.
Collaborators
—
Condition
Carcinoma, Hepatocellular
Intervention
Lenvatinib
Why stopped
Study recruitment was stopped due to difficulty in enrolling the targeted number of participants.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-12-06